Achieve Life Sciences Announces Advancement of Cytisine Development Program Following Meeting with the FDA
(World News Science)

Achieve Life Sciences Announces Advancement of Cytisine Development Program Following Meeting with the FDA SEATTLEand VANCOUVER, British Columbia, July 11, 2018/PRNewswire / -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an update on the cytisine development program following a meeting conducted with the United States(U.S.) Food and Drug Administration (FDA). The meeting with the FDA on the non-clinical and clinical development plans has further defined Achieve`s Phase 3 clinical program and expected future New Drug Application (NDA) submission....